Awarded $65.67 million from ARPA-H, the researchers will work to develop ingestible capsules that deliver mRNA and electric stimuli to treat metabolic disorders such as diabetes.

Researchers can use the model to predict how engineered forms of insulin would perform in human patients, making it easier to bring these drugs to clinical trials.

The device contains encapsulated cells that produce insulin, plus a tiny oxygen-producing factory that keeps the cells healthy.

Payton Dupuis finds new scientific interests and career opportunities through MIT summer research program in biology.

A new device, which doesn’t rely on immunosuppressing drugs, may assist efforts to develop an artificial pancreas to treat diabetes.

Chemical engineers have developed a way to protect transplanted drug-producing cells from immune system rejection.

A new model can predict which types of glucose-responsive insulin will work in humans and animals.

Noninvasive device could benefit patients with kidney disease, congestive heart failure, or dehydration.

Crystallized drug prevents immune system rejection of transplanted pancreatic islet cells.

Study may be a step toward shelf-stable versions of the hormone, which is used to control diabetes.